• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (NY: NRXS )

    2.500 -0.150 (-5.66%)
    Official Closing Price Updated: 8:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 22,483
    Open 2.450
    Bid (Size) 0.9600 (1)
    Ask (Size) 6.000 (21)
    Prev. Close 2.650
    Today's Range 2.275 - 2.600
    52wk Range 2.000 - 3.890
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024
    Neuraxis just reported results for the second quarter of 2024. 
    Via InvestorPlace
    NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024
    Neuraxis just reported results for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -1.57%
    -1.57%
    1 Month
    -17.76%
    -17.76%
    3 Month
    -12.28%
    -12.28%
    6 Month
    -21.14%
    -21.14%
    1 Year
    +2.88%
    +2.88%

    More News

    Read More
    NRXS Stock Earnings: Neuraxis Misses Revenue for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For April 9, 2024
    Via Benzinga
    With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)
    Via AB Newswire
    Exposures Product Safety
    SoftBank-Owned Arm, Instacart File To Go Public
    Via Talk Markets
    Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
    Via Benzinga
    CEO Spotlight: NeurAxis CEO Explains His Better Way Of Treating Pediatric IBS And FAP ($NRXS)
    Via AB Newswire
    NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues
    Via Benzinga
    EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
    Via Benzinga
    NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
    From NeurAxis, Inc.
    Via GlobeNewswire
    Alcoholic Beverage Marketing Company LQR Debuts On Nasdaq
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.
    Via ACCESSWIRE
    NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
    From NeurAxis, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.